Skip to content

INVESTORS & MEDIA

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
May 20, 2015
SOUTH SAN FRANCISCO, Calif., May 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the American Society of Clinical Oncology 2015 Annual Meeting website was updated for abstract 10016 being presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK). The updated abstract ad...
May 14, 2015
SOUTH SAN FRANCISCO, Calif., May 14, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at the 2015 American Societ...
May 12, 2015
SOUTH SAN FRANCISCO, Calif., May 12, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, the company's President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015 at 4:00 pm EDT in New York City. The live audio webcast of the company p...
May 7, 2015
SOUTH SAN FRANCISCO, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the first quarter ended March 31, 2015. "The first quarter was an active period for Ata...
Apr 20, 2015
SOUTH SAN FRANCISCO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) presented data on its investigational cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Plenary Sessi...
Apr 19, 2015
SOUTH SAN FRANCISCO, Calif., April 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that the abstract on cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) that will be presented by its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) at a Clinical Trials Plenary ...
Apr 13, 2015
SOUTH SAN FRANCISCO, Calif., April 13, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Isaac Ciechanover, M.D., the company's Chief Executive Officer, will present at the 2015 Jefferies Immuno-Oncology Summit on Wednesday, April 15, 2015 at 11:00 am EDT in Boston.About Atara Biotherapeutics, Inc. Atara Bi...
Apr 9, 2015
SOUTH SAN FRANCISCO, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that Gad Soffer, the company's Chief Operating Officer, will present at the 2015 Needham Healthcare Conference on Tuesday, April 14, 2015 at 5:00 pm EDT in New York City. The live audio webcast of the company presentation wil...
Mar 27, 2015
SOUTH SAN FRANCISCO, Calif., March 27, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases, today announced that Eric Dobmeier has joined its Board of Directors. Mr. Dobmeier is currently the Chief Operating Officer of ...
Mar 19, 2015
SOUTH SAN FRANCISCO, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) will present clinical data from two studies of cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) at a Clinical Trials Ple...
Mar 3, 2015
SOUTH SAN FRANCISCO, Calif., THOUSAND OAKS, Calif., and NEW YORK, March 3, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on innovative therapies for patients with debilitating diseases, announced today that it has hired David A. Carmel as Head of Immunotherapy. Mr. Carmel will lead Atara's e...
Mar 2, 2015
SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated ag...
Feb 26, 2015
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company with a focus on developing innovative therapies for patients with debilitating diseases, today reported financial results for the fourth quarter and full year ended December 31, 2014. "2014 was a significant year...
Feb 18, 2015
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the closing of its public offering of 4,147,358 shares of its common stock at a public offering price of $18.0...
Feb 12, 2015
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced the pricing of its underwritten public offering of 3,638,333 shares of its common stock at a public offering p...
= add release to Briefcase